Cancer Exports Molecular ‘Saboteurs’ to Remotely Disarm Immune System
This article is archived and only made available for historical reference. If you’d like to discover UCSF’s most recent advances in research, education and patient care, please visit the UCSF News Center. But the majority of patients don’t respond to these drugs, and they work far better in some cancers than others, for reasons that have befuddled scientists.
- ▪This article is archived and only made available for historical reference.
- ▪If you’d like to discover UCSF’s most recent advances in research, education and patient care, please visit the UCSF News Center.
- ▪But the majority of patients don’t respond to these drugs, and they work far better in some cancers than others, for reasons that have befuddled scientists.
UCSF News files mainly under design. We currently carry 50 of its stories.
Opening excerpt (first ~120 words) tap to expand
This article is archived and only made available for historical reference. If you’d like to discover UCSF’s most recent advances in research, education and patient care, please visit the UCSF News Center. Research April 4, 2019 Archive: Cancer Exports Molecular ‘Saboteurs’ to Remotely Disarm Immune System Discovery May Help Explain Immunotherapy Resistance, Hints at New Therapies By Jason Alvarez Share on Facebook Share on Twitter Share on Reddit Email this article Print this article Immunotherapy drugs known as checkpoint inhibitors have revolutionized cancer treatment: many patients with malignancies that until recently would have been considered untreatable are experiencing long-term remissions.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at UCSF News.